Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Current Liabilities (2019 - 2025)

Immunocore Holdings' Total Current Liabilities history spans 4 years, with the latest figure at $246.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 16.27% year-over-year to $246.7 million; the TTM value through Dec 2025 reached $246.7 million, up 16.27%, while the annual FY2025 figure was $246.7 million, 16.27% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $246.7 million at Immunocore Holdings, up from $170.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $266.2 million in Q3 2024 and bottomed at $100.8 million in Q4 2022.
  • The 4-year median for Total Current Liabilities is $170.2 million (2025), against an average of $179.5 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 52.63% in 2024 before it crashed 36.02% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $100.8 million in 2022, then soared by 37.87% to $139.0 million in 2023, then surged by 52.63% to $212.2 million in 2024, then rose by 16.27% to $246.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Total Current Liabilities are $246.7 million (Q4 2025), $170.4 million (Q3 2025), and $170.1 million (Q2 2025).